Gilead Sciences, Inc.: updates and filings

GILDNASDAQHealthcare · Biological Products, (No Diagnostic Substances)

Price

$168.98

November 18, 2026Market cap $210B

What Ploutos Investor adds for Gilead Sciences

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 74 daysAround Feb 1, 2027 · for Q4 2026

last Oct 29, 2026next Feb 1, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Latest dividend declared

$0.8200a sharesame as before ($0.8200)

declared Oct 29, 2026

Document

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Feb 24, 2026 latest annualOct 30, 2026 latest quarterly
  • Nov 6, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Nov 6, 2026Its own holdings as an investment manager (13F)
    Form13F-HR
  • Oct 30, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Oct 29, 2026Results of operations
    Form8-K
  • Aug 26, 2026Filing
    FormN-PX
  • Aug 7, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Aug 6, 2026Shelf registration for future offerings
    FormS-3ASR
  • Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 4, 2026Results of operations
    Form8-K
  • Aug 3, 2026Its own holdings as an investment manager (13F)
    Form13F-HR
  • May 27, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • May 20, 2026Material agreement entered, new material financial obligation, other material events
    Form8-K
  • May 8, 2026Its own holdings as an investment manager (13F)
    Form13F-HR
  • May 7, 2026Shares registered for employees
    FormS-8
  • May 7, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 7, 2026Results of operations
    Form8-K
  • May 4, 2026Shareholder vote
    Form8-K
  • Apr 29, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Apr 28, 2026Over-5% holder statement (active) (amendment)
    FormSCHEDULE 13D/A
  • Apr 28, 2026Regulation FD disclosure, other material events
    Form8-K
  • Apr 28, 2026Filing (amendment)
    FormSC TO-T/A
  • Apr 17, 2026Filing (amendment)
    FormSC TO-T/A
  • Apr 1, 2026Filing (amendment)
    FormSC TO-T/A
  • Mar 26, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Mar 20, 2026Annual report to shareholdersfor the period to Dec 31, 2025
    FormARS

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC since Feb 14, 1994: every report, 8-K, meeting and letter. Of its other filings (1,030 in all), the newest. Of its note and share prospectuses (424B, FWP), the newest 40 of 57.

The full analysis

What do Gilead Sciences's filings show?

The filings are where every one of Gilead Sciences's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.